Feb 11 (Reuters) - Crescita Therapeutics Inc CTX.TO :
* CRESCITA ANNOUNCES POSITIVE TOPLINE RESULTS FROM TWO PIVOTAL PHASE 3 CLINICAL STUDIES FOR ITS LEAD PIPELINE PRODUCT IN PATIENTS WITH PLAQUE PSORIASIS
* CRESCITA THERAPEUTICS INC - PRIMARY ENDPOINT ACHIEVED WITH HIGH STATISTICAL SIGNIFICANCE IN TRIAL
* CRESCITA THERAPEUTICS INC - BOTH PHASE 3 STUDIES MET PRIMARY ENDPOINT